I was thinking (or hoping) it might be ONC201 as well. If this were the case it might be worth keeping and eye on Chimerix. They acquired Oncoceutics in Jan 2021 specifically for their oncology program. Depending on where CMRX see ONC201 in that program they might not want to license it out?
I suspect we will get an announcement late Monday evening again and the US will trade first again.